Abstract
The cyclin-dependent kinases 4/6 inhibitors (CDK4/6i) palbociclib, ribociclib, and abemaciclib have been reported to show an association with new-onset subacute lupus erythematosus (SCLE) but CDK4/6i’s role in new-onset dermatomyositis (DM) is unexplored. We evaluated the clinical characteristics of patients presenting with new-onset DM following CDK4/6i. In this retrospective cohort study we queried data registries of Mass General Brigham and Dana-Farber Cancer Institute from October 1, 2014 - November 30, 2021, excluding patients with rash pre-initiation or post-termination of CDK4/6i.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
